Donostia

• A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended recruitment
  2024-510887-22-00 5 2019-09-30 Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
• Trial of dostarlimab (TSR-042) for patients with high-risk locally advanced cervical cancer after chemo-radiation Ended recruitment
  2023-510268-11-00 4 2019-06-11 Cervical cancer
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• Study of durvalumab or placebo administered with radiation therapy for patients with early stage non-small cell lung cancer Study of osime … Ended recruitment
  2024-512667-31-00 5 2019-04-23 Main cohort: Patients with unresected Stage I/II, lymph-node negative
• A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended recruitment
  2023-509576-42-00 5 2019-02-21 Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year … Ended recruitment
  2024-516905-22-00 5 2018-10-22 Multiple myeloma
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi … Ended recruitment
  2024-510967-41-00 5 2018-09-21 Metastatic colorectal cancer
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Res … Ended recruitment
  2023-508726-10-00 5 2018-03-28 Hepatocellular Carcinoma
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl … Ended recruitment
  2023-506524-82-00 5 2015-10-21 Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone … Ended recruitment
  2024-515368-29-00 5 2012-09-20 patients with node positive breast cancer who do not have high Recurre
• Study of CC-97540 (BMS-986353), CD19-CAR T Cells, in Participants with Active SLE Despite Immunosuppressants (Breakfree-SLE) Halted
  2024-519278-37-00 4 2025-10-22 Lupus Nephritis
• Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for … Ended
  2023-509257-31-00 1 2025-02-12 Alzheimer’s Disease in Individuals with Down Syndrome
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Ended
  2022-502713-29-00 5 2024-03-01 Dyskinesia due to cerebral palsy (DCP)
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation
• CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy 2 (CHOICE2TRIAL) Ended
  2023-504262-32-01 5 2023-11-16 Cerebral Embolectomy in patients with acute stroke
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 4 2023-09-29 Large B-Cell Lymphoma (LBCL)
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy

Showing 145–168 of 200 trials